NAD+ (Nicotinamide Adenine Dinucleotide)

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, central to energy metabolism and to several signalling pathways. It is not absorbed intact when taken by mouth. Products marketed as "NAD+ supplements" deliver one of several precursor molecules — niacin, nicotinamide, nicotinamide riboside (NR), or nicotinamide mononucleotide (NMN) — that the body converts to NAD+. These precursors have very different UK regulatory statuses, and the marketing claims around NAD-level marketing and age-reversal positioning are not authorised for use in UK food-supplement labelling.

Camden Medicals editorial · Last reviewed 2 September 2026 · Next review December 2026

  • Cross-checked against
  • NHS
  • NICE
  • BNF
  • EFSA
  • FSA
Verifera Evidence ReviewCamden’s own editorial review · evidence-graded, verification in progress — graded, not guessed.

Camden's own editorial team graded each health claim below on the strength of the published evidence — trials weighed with Cochrane RoB 2, systematic reviews with AMSTAR 2, under the CEGA method. See the grade beside every condition.

Class
Nucleotide
Typical daily dose
NR clinical trials have most commonly used 250–1000 mg/day. Niacin / nicotinamide at vitamin B3 NRV-level intakes (16 mg/day) suffice for the authorised claims. NMN: GB authorisation pending; the only regulator-assessed intake is EFSA's 2026 safety ceiling of 300 mg/day for adults (excluding pregnancy and lactation) — no "typical" dose is listed because no health effect has been assessed at any dose.
Top use evidence
Strong
On this page
  1. What it is
  2. At a glance
  3. What people use it for
  4. How it works
  5. Common myths
  6. Common online questions
  7. The official position
  8. Authorised UK claims
  9. Camden's evidence review
  10. Safety, interactions & who should avoid it
  11. How to take it
  12. How to spot quality
  13. Commonly combined with
  14. Related ingredients
  15. Sources

What it is

NAD+ is a coenzyme made of two nucleotides linked by a phosphate bridge. It is essential for hundreds of redox reactions in mitochondria (notably oxidative phosphorylation), DNA repair via PARP enzymes, and sirtuin signalling. It is present in every living cell, regenerated continuously, and obtained from the diet via several precursor molecules collectively grouped as the vitamin B3 family of NAD building blocks.

Oral NAD+ does not survive intact through digestion and is not absorbed in any meaningful quantity as the intact molecule. To raise intracellular NAD+, the body relies on absorbing precursors and processing them through the salvage pathway. The relevant precursors:

- Nicotinic acid (NA / niacin). Vitamin B3, classical form. UK
RNI 16 mg/day (men), 12 mg/day (women). Authorised health claims
apply. High doses cause cutaneous flush.

- Nicotinamide (NAM). Vitamin B3, amide form. Same RNI as NA;
no flush. Both NA and NAM raise NAD+ via the salvage pathway.

- Nicotinamide riboside (NR). A glycoside form of NAM linked
to ribose. Authorised in GB as a novel food (the Niagen®
preparation by ChromaDex was the first authorised). Sold legally
as a UK food supplement.

- Nicotinamide mononucleotide (NMN). A direct precursor of
NAD+ in the salvage pathway. In Great Britain NMN is a novel
food that is NOT YET authorised: a GB determination has not been
made (FSA application in progress), and products linked to an
in-process application may remain on sale under the transitional
arrangements — this is not a prohibition. In the EU, EFSA's NDA
Panel adopted a positive safety opinion on β-NMN in 2026 (EFSA
Journal DOI 10.2903/j.efsa.2026.10007): up to 300 mg/day judged
safe for adults, excluding pregnant and lactating women, as a
source of niacin — a safety and bioavailability opinion, not a
health-claim endorsement, and intakes above 300 mg/day were not
evaluated. A European Commission authorisation decision is
pending. Camden Medicals stocks NMN under transparent disclosure
of this status and makes no health claims on it.

The most-marketed framings — boosting NAD+ with NMN, reversing cellular age, lifespan-supplement positioning — are EFSA-on-hold or unauthorised claims regardless of precursor. The vitamin B3 claims at NRV-level intake are authorised; the lifespan-marketing framings are not.

At a glance

  • NAD+ itself is not absorbed intact when taken orally. "NAD+ supplements" are NAD precursors.
  • The four common precursors: nicotinic acid (niacin / NA), nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). They are NOT regulatory equivalents.
  • Niacin and nicotinamide are vitamin B3 — they have UK-authorised claims (energy metabolism, nervous-system function, etc.) at standard NRV intakes.
  • NR is a GB-authorised novel food (Niagen® preparation). UK food supplements containing NR are legal.
  • NMN is a novel food that is NOT YET authorised in GB — a GB determination has not been made (FSA application in progress) and products linked to an in-process application may stay on sale under the transitional arrangements; this is not a prohibition. In the EU, EFSA adopted a POSITIVE safety opinion in 2026: safe for adults at up to 300 mg/day (excluding pregnancy and lactation) — a safety opinion, not an authorisation and not a health claim. Reputable UK sellers state this status plainly and make no health claims on NMN.
  • Marketing that promises age reversal, a longer lifespan, or a "NAD+ boost" makes claims UK regulation does not authorise — treat it with caution.

What people use it for

  • Adults wanting to meet vitamin B3 requirements

    Niacin or nicotinamide at the UK NRV (16 mg) supports the authorised vitamin-B3 claims (energy metabolism, nervous system, psychological function, normal skin and mucous membranes, reduction of tiredness and fatigue). Most balanced UK diets meet this without supplementation. [2,1]

    Some evidenceStrong

  • Adults exploring NAD-precursor supplementation for lifespan or energy outcomes

    Trials show that NR raises blood NAD+ markers reliably and is generally well-tolerated. Translation to meaningful health outcomes in healthy adults is not established. Lifespan-marketing claims, age-reversal claims, and NAD-level boosting claims are not UK-authorised health claims.

    Some evidenceLimited

  • UK consumers considering NMN

    NMN is a GB novel food whose authorisation is pending (FSA assessment in progress; transitional arrangements apply — not a prohibition). EFSA's 2026 opinion judged it safe for adults at up to 300 mg/day, excluding pregnancy and lactation; that is a safety finding, not a health claim. Buy from a UK seller that states this status on the product page, names the dose per capsule, and makes no health claims; imported NMN from non-UK e-commerce carries no such disclosure and no UK body has verified its composition, contamination, or label accuracy. [3]

    Popular, not provenInsufficient

  • People with diagnosed mitochondrial conditions or rare metabolic disorders

    These conditions are managed in specialist NHS services. Self-supplementation with NAD-building precursor molecules is not the appropriate pathway; talk to your specialist team.

    Popular, not provenInsufficient

How it works

Cellular NAD+ levels decline modestly with age and in some chronic disease states. Animal and laboratory work has shown that supplementing precursors raises NAD+ in tissues, with downstream effects on sirtuin activity, mitochondrial function and PARP-mediated DNA repair signalling. Human trials of NR and (in non-UK markets) NMN have demonstrated raised blood NAD+ markers reliably; the clinical translation of those biochemical changes to meaningful health outcomes in healthy adults remains an active research area without consensus.

Common myths

Myth"Taking NAD+ pills directly raises NAD+ in my cells"

RealityOral NAD+ is degraded in digestion and is not absorbed intact in meaningful quantities. The body relies on precursor absorption and intracellular conversion. Products marketed as "NAD+" are delivering precursors.

Myth"NMN is a natural substance and therefore legal in the UK as a supplement"

RealityNaturalness does not determine UK supplement legality — Novel Foods regulations do. NMN is a GB novel food whose authorisation is still pending (FSA assessment in progress, transitional arrangements apply) — and "natural" played no part in EFSA's 2026 safety opinion either, which rested on toxicology and a 300 mg/day margin of exposure. Imported NMN bought from non-UK e-commerce is not "regulated" by virtue of arriving in the UK. [3]

Myth"NR will let me skip exercise and a balanced diet"

RealityIt will not. Whatever benefits NR may provide, they are not a substitute for the established interventions that actually produce measurable health outcomes — sleep, exercise, dietary adequacy. UK NICE pathways for cardiovascular and metabolic health do not list NAD-building precursor molecules.

Myth"NAD+ supplements reverse ageing"

RealityAge-reversal is not an authorised UK health claim for any ingredient — the GB NHC Register has no such category. Marketing that uses this framing is operating outside both the evidence base and UK supplement-marketing rules. [2]

Common online questions

Synthesised from the questions UK shoppers most often ask online about NAD+ (Nicotinamide Adenine Dinucleotide). Each answer is editorial and links to its evidence in the Sources list below.

Can I just take NAD+ directly?

Oral NAD+ is broken down in digestion and is not absorbed intact in any meaningful quantity. The body relies on absorbing precursors (niacin, nicotinamide, NR, NMN) and converting them intracellularly. Products marketed as "NAD+" almost always deliver a precursor; check the ingredients panel.

Is NMN legal in the UK?

NMN is a novel food in Great Britain and is not yet authorised: the FSA's assessment of the application is in progress, and products linked to an in-process application may remain on sale under the transitional arrangements. That is a pending status, not a ban. EFSA (the EU risk assessor) adopted a positive safety opinion in 2026 — safe for adults at up to 300 mg/day, excluding pregnancy and lactation — which is a safety finding, not an authorisation and not a health claim. A responsible UK seller states this status on the product page and makes no health claims on NMN; imported NMN from non-UK e-commerce carries no such disclosure. [3]

Is NR (nicotinamide riboside) any better than ordinary niacin or nicotinamide?

NR raises blood NAD+ markers in human trials reliably, more markedly than equivalent doses of nicotinamide in some studies. Whether that biochemical difference translates into meaningful health outcomes for healthy adults is not established. Niacin and nicotinamide carry the authorised UK vitamin-B3 health claims; NR does not (it is regulated as a novel food, not a named vitamin form, on the GB NHC Register). [2]

Will NAD+ supplements reverse ageing?

No UK-authorised health claim allows that framing for any ingredient. Animal data on sirtuin signalling and mitochondrial function has driven the marketing language, but no human trial has demonstrated that any NAD-building molecule reverses ageing as a clinical outcome. Marketing that claims this is operating outside both the evidence base and UK supplement-marketing rules. [2]

I read about NAD+ infusions / IV drips — are they regulated?

IV NAD+ administration sits outside food-supplement regulation and outside any standard UK clinical pathway. UK pharmacists and NHS services do not offer IV NAD+ as a standard service. Private clinics offering it operate under separate professional-conduct frameworks. Talk to your GP before any infusion-based intervention.

⚖️ The official position

What may lawfully be claimed about NAD+ (Nicotinamide Adenine Dinucleotide) in Great Britain. This is a regulatory position, not an evidence grade.

No health claim is authorised for NAD+ (Nicotinamide Adenine Dinucleotide) in Great Britain.

This page describes the evidence and online discussion without making a claim.

Authorised UK health claims

Verbatim from the GB Nutrition and Health Claims Register (Reg 432/2012 as assimilated in GB). A product can carry these claims when it provides at least 15% of the UK NRV per recommended daily portion.

6 authorised claims — show / hide
  • "Niacin contributes to normal energy-yielding metabolism"
  • "Niacin contributes to normal functioning of the nervous system"
  • "Niacin contributes to normal psychological function"
  • "Niacin contributes to the maintenance of normal mucous membranes"
  • "Niacin contributes to the maintenance of normal skin"
  • "Niacin contributes to the reduction of tiredness and fatigue"

UK regulatory landscape

UK regulatory tier: Food supplement

EFSA claim status

Anti-ageing, longevity, and "raises NAD+" claims are unauthorised health claims and must not appear on labels or marketing. They are not "on hold" — they are not within the EFSA / UK approved-claims framework.

UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.

🔬 Camden’s evidence review

The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.

  1. Raising blood NAD+ in healthy adults (NR)

    Evidencestrong

    Multiple human RCTs of nicotinamide riboside (NR) at 250–1000 mg/day for 4–12 weeks have reliably raised blood NAD+ markers. Trial sizes are modest, but the biochemical pharmacodynamics are well-replicated. [7,8,9]

  2. Clinical health outcomes in healthy adults (NR)

    Evidencelimited

    Beyond the biochemical effect on blood NAD+, larger and longer trials are needed to establish meaningful changes in measures consumers care about (energy, sleep, exercise capacity, cognition, cardiovascular markers). Existing trial data is mixed and sample sizes are small.

  3. NMN — clinical evidence in non-UK trials

    Evidencelimited

    Trials of NMN, mostly outside the UK, have reported similar biochemical effects to NR on blood NAD+. UK consumers should note that this evidence base does not change the GB regulatory position — NMN remains a novel food not yet authorised in GB (transitional arrangements, FSA assessment in progress). EFSA's 2026 opinion assessed SAFETY at up to 300 mg/day; it did not assess, and does not endorse, any health effect.

Safety

Niacin and nicotinamide at vitamin-B3 NRV intakes (16 mg/day) are well-established and well-tolerated. Higher-dose precursor supplementation (NR at 250–1000 mg/day) is generally well-tolerated in trials. NMN is a GB novel food with authorisation pending; EFSA judged it safe at up to 300 mg/day for adults (excluding pregnancy and lactation) in 2026 — buy only where the seller states that status and the per-capsule dose.

Talk to your pharmacist or GP first if you:

  • You take medicines metabolised in the liver at high doses of nicotinamide (>500 mg/day) — discuss hepatic monitoring.
  • You take statins or fibrates at the same time as high-dose nicotinic acid — risk of myopathy.
  • You take prescribed diabetes medication — high-dose niacin can affect glycaemic control.
  • You have liver disease or a history of hepatic adverse reactions.
  • You are pregnant or breastfeeding — limited supplemental-dose data for NR / NMN; standard B3 RNI applies.

Common side effects: High-dose nicotinic acid (≥30 mg) causes a cutaneous flush — warm, prickly, red skin lasting ~30 min — common and harmless but uncomfortable. Nicotinamide and NR generally do not flush. GI complaints possible at higher doses.

Pregnancy and breastfeeding

Standard vitamin B3 RNI applies in pregnancy; high-dose NR / NMN supplementation is not established as safe in pregnancy. Talk to your pharmacist or GP before supplementing with NAD-building precursor molecules during pregnancy.

Standard vitamin B3 RNI applies in breastfeeding; high-dose precursor data is limited.

Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.

More clinical detail (for clinicians and informed readers)

Contraindications

  • Active liver disease — discuss with GP before taking high-dose precursors.
  • Known hypersensitivity to the specific precursor or supplement constituents.

Drug interactions

  • Statins / fibrates with high-dose nicotinic acid — myopathy risk.
  • Prescribed diabetes medication with high-dose niacin — glycaemic-control interaction.
  • Allopurinol with high-dose niacin — uric acid effects.

This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.

Common side effects

  • Nicotinic acid: cutaneous flush at ≥30 mg single dose — warm, prickly, red skin and scalp; lasts ~30 min; harmless but uncomfortable.
  • Nicotinamide / NR: mild GI complaints at higher doses; generally well-tolerated.

Rare side effects

  • Hepatic adverse reactions at high (medicinal-range) nicotinic acid or nicotinamide doses.
  • Glucose intolerance / worsening glycaemic control with high-dose niacin.

How to take it

Typical supplemental range
NR clinical trials have most commonly used 250–1000 mg/day. Niacin / nicotinamide at vitamin B3 NRV-level intakes (16 mg/day) suffice for the authorised claims. NMN: GB authorisation pending; the only regulator-assessed intake is EFSA's 2026 safety ceiling of 300 mg/day for adults (excluding pregnancy and lactation) — no "typical" dose is listed because no health effect has been assessed at any dose.
Timing
No specific timing requirement.

How to spot quality

Look for

  • Precursor form named clearly: niacin, nicotinamide, nicotinamide riboside (NR), or nicotinamide mononucleotide (NMN). "NAD+" alone on a label is marketing shorthand for a precursor.
  • For NR products: licensed Niagen® mark from ChromaDex (the GB-authorised novel-food preparation).
  • Per-serving dose stated in mg of the precursor.
  • Country of manufacture and GMP certification.
  • Avoidance of age-reversal, lifespan-marketing, and NAD-level boosting claims on the label — these are not UK-authorised.

Red flags

  • NMN sold WITHOUT its GB novel-food status stated (authorisation pending, transitional arrangements), or with NAD+/anti-ageing claims, or at more than 300 mg/day without saying that exceeds the EFSA-assessed intake.
  • "NAD+" on the label without naming which precursor.
  • Age-reversal / lifespan-marketing / "reverses ageing" / "cellular rejuvenation" claims.
  • Imported "NAD+" products from non-UK marketplaces sold to UK consumers without GB authorisation context.
  • IV NAD+ services advertised alongside oral supplements, blurring food-supplement and clinical-procedure regulation.

Commonly combined with

Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.

NMN (β-Nicotinamide Mononucleotide)

Limited evidence

NAD+-precursor cluster — NAD+ end-product + NMN upstream precursor.

NMN (β-nicotinamide mononucleotide) is the direct NAD+ precursor via NMNAT pathway. NAD+ supplementation directly is poorly absorbed orally; NMN (or NR) is the more-absorbed route. Camden nmn NB-161 covers FSA novel-food regulatory-watch context.

Evidence: Camden nmn is the cluster reference.

Doses studied: Use NMN 250-1000 mg/day OR niacinamide 16 mg/day — NAD+ direct supplementation has poor oral bioavailability.

Found in Camden: Clarifera® NMN Complex 90 Delayed Release Capsules

Vitamin B3 (Niacin / Nicotinamide)

Insufficient evidence

NAD+-precursor cluster — B3 (niacin / nicotinamide) is the upstream salvage-pathway precursor.

Niacin → nicotinamide → NAD+ via Preiss-Handler / salvage pathway. UK Article 13.1 B3 energy-metabolism claim.

Evidence: UK Article 13.1 B3 claim.

Doses studied: 16 mg B3 daily (UK NRV) covers salvage pathway.

Pterostilbene (trans-pterostilbene)

Limited evidence

NAD+ adjunct — pterostilbene is the resveratrol analogue that some NMN products combine for sirtuin / mitochondrial-biogenesis framing.

Pterostilbene is bioavailable resveratrol analogue; sirtuin-activator framing. Combined with NMN in some commercial products (Niagen, Tru Niagen, other branded NAD+-precursor blends).

Evidence: Camden pterostilbene + nmn NB-161 cluster.

Doses studied: NMN 250-1000 mg + pterostilbene 50-100 mg daily.

Found in Camden: Clarifera® NMN Complex 90 Delayed Release Capsules

Related ingredients

Sources

Numbered references cited above plus general authoritative reading. Citations in the body link to the matching number here.

How to read these sources:

  • Tier 1 (UK authoritative): NHS, NICE, BNF, EFSA, FSA, GB NHC Register, SACN, MHRA.
  • Tier 2 (primary literature): peer-reviewed RCTs cited by PMID.
  • Tier 3 (mechanistic): in-vitro / animal-model literature — interpret with caveat.
  1. NHS — B vitamins and folic acid
  2. GB Nutrition and Health Claims Register (gov.uk)
  3. FSA — Novel Foods guidance (UK)
  4. FSA — Authorised novel foods register
  5. EFSA — Scientific Opinion on the safety of nicotinamide riboside chloride (Niagen®) (2019)
  6. NIH ODS — Niacin Fact Sheet for Health Professionals
  7. PubMed PMID 31278280
  8. PubMed PMID 29599478
  9. PubMed PMID 36515353

Verifera® is published by Camden Medicals — a UK supplement retailer. We have a commercial interest in some of the ingredients described here; we declare it on every page and our editorial process forbids adjusting copy to favour our own products. Read our editorial policy.

This page is information, not medical advice. Talk to your pharmacist or GP before starting any supplement, especially if you take prescribed medicines, are pregnant or breastfeeding, or have an existing condition.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme: yellowcard.mhra.gov.uk